Alzheimer’s Blood Test Predicts Who Might Benefit Most From Anti-Amyloid Drugs
Plasma phosphorylated tau 217 (p-tau217) outperformed p-tau181, p-tau231, and other blood-based biomarkers to identify which patients might benefit most from anti-amyloid Alzheimer’s drugs, a cohort study showed. Plasma p-tau217 helped rule out two groups who would not likely benefit: those who were amyloid-negative, and those who were amyloid-positive but had a high tau burden, reported […]